Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management

Hiroyuki Yajima, Hajime Isomoto, Hiroaki Nishioka, Naoyuki Yamaguchi, Ken Ohnita, Tatsuki Ichikawa, Fuminao Takeshima, Saburo Shikuwa, Kazuhiro Nakao, Kazuhiro Tsukamoto, Shigeru Kohno

Hiroaki Nishioka, Kazuhiro Tsukamoto, Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University School of Medicine, Nagasaki 852-8521, Japan

Masahiro Ito, Department of Pathology, National Nagasaki Medical Center, Omura, Nagasaki 856-0835, Japan

Author contributions: Isomoto H and Tsukamoto K contributed to study design; Yajima H, Nishioka H, Ohnita K, Shikuwa S and Ito M contributed to data collection; Yamaguchi N and Ichikawa T contributed to data analysis; Takeshima F and Nakao K contributed to data interpretation; Isomoto H, Yajima H and Kohno S contributed to manuscript preparation; Isomoto H, Yajima H and Tsukamoto K contributed to literature search.

Correspondence to: Hajime Isomoto, MD, Department of Gastroenterology and Hepatology, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. hajimei2002@yahoo.co.jp

Telephone: +81-95-8199481 Fax: +81-95-8197482
Received: June 8, 2012 Revised: December 5, 2012
Accepted: December 15, 2012 Published online: March 16, 2013

Abstract

AIM: To explore mutations in serine/threonine kinase 11 (STK11) gene in Peutz-Jeghers syndrome (PJS) with gastrointestinal (GI) hamartomatous polyps.

METHODS: Six Japanese PJS patients in 3 families were enrolled in this study. Each of the cases had hamartomatous polyposis in the gastrointestinal tract, including the small intestine, along with mucocutaneous hyperpigmentation. Narrow-band imaging (NBI)-magnification endoscopy was employed to detect microvascular and microsurface irregularities in the GI lesions. NBI magnification findings could be classified into three groups (type A, type B, or type C). Endoscopic polypectomy was performed using double-balloon enteroscopy or colonoscopy. Genomic DNA was extracted from a whole blood sample from each subject. All of the coding exons of STK11 gene, its boundary regions, and the promoter region containing the polymorphic regions were amplified by polymerase chain reaction, and direct sequencing was performed to assess the germline mutations.

RESULTS: NBI-magnification endoscopic observation could detect the abnormalities in microvessels and microsurface structures of GI polyps. Overall, we found 5 cases of type A and one case without the examination for the gastric polyps, while there were 4 cases of type B and 2 case of type A for the colorectal polyps. Seventy-nine small-bowel and 115 colorectal polyps over 27 sessions for each were resected endoscopically without significant complications. The only delayed complication included the occurrence of bleeding in a case, and this was successfully managed with hemoclips. Resected polyps contained no malignant components. Based on mutation analysis, all 3 cases in Family I exhibited the +658C>T nonsense mutation in exon 5, which resulted in the production of a truncated protein (Q220X). In Family II, a case had -252C>A and -193C>A in the promoter region. In Family III, a case was found to have the +1062C>G (F342L) mutation in exon 8.

CONCLUSION: We found two novel mutations of STK11 in association with PJS. Endoscopic polypectomy of GI polyps in PJS patients appears to be useful to prevent emergency laparotomies and reduce the cancer risk.

© 2013 Baishideng. All rights reserved.
Yajima H et al. STK11 and endoscopic management in PJS

**Key words:** Peutz-Jeghers syndrome; Serine/threonine kinase 11; Gastrointestinal hamartomatous polyps; Double-balloon enteroscopy; Narrow-band imaging

Yajima H, Isomoto H, Nishioka H, Yamaguchi N, Ohnita K, Ichikawa T, Takeshima F, Shikuwa S, Ito M, Nakao K, Tsukamoto K, Kohno S. Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. *World J Gastrointest Endosc* 2013; 5(3): 102-110 Available from: URL: http://www.wjgnet.com/1948-5190/full/v5/i3/102.htm DOI: http://dx.doi.org/10.4253/wjge.v5.i3.102

**INTRODUCTION**

Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant hereditary condition with incomplete penetrance that is characterized by hamartomatous polyps of the gastrointestinal (GI) tract and pigmented lesions of the buccal mucosa, perioral region and other sites. Variable penetrance and clinical heterogeneity make it difficult to determine the exact frequency of PJS. Most PJS patients develop significant hamartomatous polyps of the small bowel, with these polyps commonly arising in the stomach and colorectum. PJS patients also have an increased risk of cancer at multiple locations, although it is predominantly found in the colon, small intestine, stomach, esophagus, pancreas, breast, ovary and uterine cervix.

PJS occurrence is primarily associated with germline mutations in the serine/threonine kinase 11 (STK11/LKB1) gene, which are localized on the chromosomal segment 19p13.3. The gene spans 23 kb, and consists of nine coding exons and a final noncoding exon. The coded protein plays a role in cellular energy metabolism, cell polarization, p53-dependent apoptosis, and Wnt signal transduction. The germline mutation detection rates in PJS patients vary among reports, but recent studies which have searched for germline mutations using state-of-art techniques demonstrate between 80% and 94%. Most mutations are single base substitutions/insertions or small deletions that result in an abnormal truncated protein.

Narrow-band imaging (NBI) is a recent innovative optical technique that modifies the center wavelength and bandwidth of an endoscope’s light in order to produce narrow-band illuminations of 415 and 540 nm. When combined with magnifying endoscopic observation, NBI can markedly improve the capillary pattern contrast. Use of this *in vivo* method makes it possible to visualize microvascular morphological changes that take place in the superficial neoplastic lesions. Several studies have reported on the advantages of using magnification endoscopy NBI for diagnosis of gastrointestinal neoplasia. Additionally, studies have also shown that when magnification chromoendoscopy is used in combination with crystal violet staining, the information obtained can be used to diagnose gastrointestinal tumors.

However, PJS patients are subject to serious complications such as intussusception and bleeding from the GI, in particular from small intestinal polyps. Therefore, many of these patients often need to undergo multiple laparotomies with intestinal resection, which can ultimately result in short-bowel syndrome and/or severe obstructions such as intussusception and bleeding from the GI, in particular from small intestinal polyps. In order to control these small-bowel polyps, a combined endoscopic and surgical treatment procedure has been designed for use in these patients. Even with the new treatment regimen, however, many of these patients still end up undergoing multiple surgical treatments because of the appearance of new lesions or the growth of existing polyps. Double-balloon endoscopy (DBE) was developed as a new technique for visualization of, and intervention in the lesions that occur throughout the entire small intestine. DBE has been reported worldwide to be useful for both diagnosis and treatment of small intestinal polyps. As such, the use of DBE could potentially be a means of providing prophylactic polypectomy in PJS patients, thereby helping to prevent the intussusception and bleeding complications.

In the current study, we performed a mutation analysis of STK11 in three PJS families. This study also presents data on the magnified endoscopy findings and the endoscopic treatments for the polyps.

**MATERIALS AND METHODS**

**Subjects**

PJS patients in 3 families were enrolled in this study (Figure 1). The PJS diagnosis was based upon clinical criteria proposed in 1987.

To definitively diagnose PJS in individuals with histopathologically confirmed hamartoma, two of the following three findings are required: (1) family history consistent with autosomal dominant inheritance; (2) mucocutaneous hyperpigmentation; and (3) small-bowel polyposis. In the current study, each of the cases had hamartomatous polyposis in the gastrointestinal tract, including the small intestine, along with mucocutaneous hyperpigmentation on the hands, feet or lips.

**Magnifying endoscopy**

We performed NBI magnification gastroscopy and colonoscopy in each PJS case. The endoscopic system included a light source (CLV-260SL; Olympus, Tokyo, Japan), a processor (CV-260SL; Olympus, Tokyo, Japan), and a high-resolution magnifying endoscope (GIF-H260Z for the stomach and CF-H260AZI for the colorectum; Olympus). The unique features of PJS polyp are best appreciated in the larger PJS small intestine polyps, but the other polyps do not have specific gastrointestinal endoscopic findings. They can be similar to hyperplastic polyps. Recently, Lam-Himlin et al. investigated the histologic features of gastric polyps in patients with established PJS to develop improved histologic criteria to distinguish these from gastric hyperplastic polyps. Histologic features to distinguish gas-
tric PJS from gastric hyperplastic polyps were unreliable. There has been no available NBI classification for gastric non-neoplastic polyps including hamartomatous and hyperplastic polyps. Kanao et al [17] reported that NBI magnification findings could be classified into three groups (type A, type B, or type C) based on their microvessel architecture and pit appearance. In type A lesions, microvessels are not observed or are extremely opaque. Type B lesions exhibit fine microvessels around the pits, with clear pits observed via a nest of microvessels. Type C lesions exhibit irregular microvessels in which the vessel diameters or distributions are heterogeneous. Type C can be further divided into 3 subtypes (C1, C2, and C3) based on the detailed NBI magnification findings for the pit visibility, vessel diameter, irregularity, and distribution. Lesions are considered to be subtype C1 when the microvessels comprise an irregular network, the pits are slightly non distinct when observed via the microvessels, and the vessel diameters or distributions are homogeneous. For the C2 subtype, microvessels comprise an irregular network, the pits are irregular when observed via the microvessels, and the vessel diameters or distributions are heterogeneous. For the type C3 subtype, the pits via the microvessels are invisible, the irregular vessel diameters are thick or there is a heterogeneous vessel distribution, along with the observation of avascular areas.

Procedures of polypectomy via DBE and colonoscopy
For the small intestinal polyps, we used an EN-450T5/W double-balloon endoscope (Fujifilm, Tokyo, Japan), which has an accessory channel that is 2.8 mm in diameter. This scope made it possible to use a variety of therapeutic devices, including an endoscopic hemoclip. For polypectomy of the colorectal polyps, we used a CF-Q260AI colonoscope (Olympus). All of the procedures were performed by specialists (Yajima H, Isomoto H, Ohnita K, Shikuwa S). While moderate sedation with a combination of intravenous pethidine and diazepam and/or midazolam was administered to most patients, general anesthesia was used in symptomatic intussusception cases. A combined oral and anal approach was performed during the first session. If polyps were recognized, careful observation was performed in order to determine their size, shape, and location. Resected polyp sizes were estimated by visual measurement. To avoid post-polypectomy bleeding and thermal injury of the deeper tissue layers, a saline-epinephrine solution (0.9% sodium chloride, 0.001% epinephrine, 0.002% indigo carmine) was injected, as needed, into the submucosal layer of the stalk and the base of the polyp prior to the polypectomy. Snare cautery polypectomy was performed using commercially available snare up to 33 mm in diameter.

Polymarker chain reaction and direct sequencing
After obtaining written informed consent, a whole blood sample was collected from all the patients for the analysis of the STK11 gene mutation. Genomic DNA was extracted from a whole blood sample from each subject using a DNA Extractor WB-Rapid Kit (Wako, Osaka, Japan) in accordance with the manufacturer's protocol. All of the coding exons of the STK11 gene, its boundary regions, and the promoter region containing the polymorphic regions were amplified by polymerase chain reaction (PCR) (Figure 2). Amplification was performed with a GeneAmp PCR System 9700 thermal cycler (Life Technologies, Carlsbad, CA) using 20 ng genomic DNA in a 25-μL reaction mixture containing 1X GoTaq Green Master Mix (Promega, Madison, WI) and 15 pmol each of forward and reverse primers (Table 1). The amplification protocol consisted of initial denaturation at 95 °C for 2 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 64 °C for 30 s, extension at 72 °C for 30 s, and a final extension at 72 °C for 5 min.

The PCR products were treated with ExoSAP-IT (Amersham Pharmacia Biotech, Piscataway, NJ) and then cycle sequenced using a BigDye Terminator v3.1 Cycle
RESULTS

The proband in Family I was a 52-year-old male (Case 1) without malignancy, who underwent a laparotomy for polypectomy of small intestinal polyps. His 26-year-old daughter was diagnosed as having cervical cancer, and subsequently underwent hysterectomy (Case 2). In addition, this daughter also underwent laparotomy four times for polypectomy of small intestinal polyps and related intussusceptions. Another daughter, who is 22 years old, has had no reported malignancies as of the present time (Case 3), although she has undergone laparotomy for small intestinal polyps.

In Family II, a 65-year-old female (Case 4) was diagnosed with pancreatic cancer, and underwent pancreatoduodenectomy. After further being diagnosed with intraepithelial neoplasia, she underwent an endoscopic submucosal dissection, and had a laparotomy for polypectomy of small intestinal polyps. Her 37-year-old daughter (Case 5) was diagnosed with colon cancer, and had a colectomy. Subsequently, she was also found to have a benign ovarian tumor, in addition to undergoing laparotomy on three separate occasions for polypectomy of small intestinal polyps and related intussusceptions. In Family III, a laparotomy was performed in a 27-year-old female who at the present time has exhibited no malignancies (Case 6).

Magnified endoscopic findings

Table 2 summarizes the NBI magnification endoscopic findings. Overall, we found 5 cases of type A (Figure 3A) and one case without the examination for the gastric polyps, while there were 4 cases of type B (Figure 3B) and 2 case of type A for the colorectal polyps.

Polypectomy

As seen in Table 3, we resected a total of 79 small-bowel polyps over 27 sessions, with a mean number of resected polyps per patient of 13.2 (range 1 to 31). The only delayed complication noted in the PJS patients was the occurrence of bleeding in Case 6, and this was successfully managed with hemoclips. Otherwise, there were no serious complications related to the therapeutic DBE. A total of 115 colorectal polyps were resected over 27 sessions, with the mean number of resected polyps per patient calculated to be 19.2 (range 0 to 39). There were also no complications associated with the colorectal pol-

### Table 1 Sequences of forward and reverse primers which are employed for analysis of germline mutations of serine/threonine kinase 11 gene

| Primer         | Sequence                  |
|----------------|---------------------------|
| STK11-5UTR-F   | GGCCGTGTTCATATCGTGGCC     |
| STK11-Ex1-F    | GTCGGCGCCAGCCATGGCCAG     |
| STK11-Ex1-R    | GGAAGAAGTACACCCAGGAGG     |
| STK11-Ex2-F    | TCCCACAGCACTGTGAGTG       |
| STK11-Ex2-R    | AGTGCGCGGGGTGAGGAGG       |
| STK11-Ex3-F    | TTTCAGAGGCGGGGAGGAGG     |
| STK11-Ex3-R    | CTGGGCGAGGAGGAGGAGG       |
| STK11-Ex3-R-2  | CAGAAGAAGTACACCCAGGAGG    |
| STK11-Ex4-F    | GCTGGAGATCCACCGTTCCCTG    |
| STK11-Ex4-R    | ACCACCCCACTGGGTGAGG       |
| STK11-Ex5-F    | CACCACGAGATGCCACGAGG     |
| STK11-Ex5-R    | AGTGCGCGGGGTGAGGAGG       |
| STK11-Ex6-F    | TGGGTGAAGACTGCGTGCAGG    |
| STK11-Ex6-R    | ACCACGCGGAGGAGGAGG       |
| STK11-Ex7-F    | AGTGCGCGGGGTGAGGAGG       |
| STK11-Ex7-R    | ACCACGCGGAGGAGGAGG       |
| STK11-Ex8-F    | CATGGTGAAGACTGCGTGCAGG    |
| STK11-Ex8-R    | ACCACCGGAGGAGGAGG       |
| STK11-Ex9-F    | GCAGCAGGCGGAGGAGGAGG     |
| STK11-Ex9-R    | AGTGCGCGGGGTGAGGAGG       |

STK11: Serine/threonine kinase 11.

Sequencing FS Ready Reaction Kit (Life Technologies). The cycle sequencing was hot-started at 96 °C for 30 s, followed by 25 cycles of denaturation at 96 °C for 10 s, annealing at 50 °C for 5 s, and extension at 60 °C for 4 min using 1 pmol PCR forward or reverse primer. Sequencing reaction solutions were purified using Sephadex G-50 superfine columns (Amersham Pharmacia Biotech), followed by drying and sequencing of the samples with an ABI Prism 3100 Genetic Analyzer (Life Technologies). All of the coding exons of the STK11 gene, its boundary regions, and the promoter region were amplified by PCR in accordance with the standard literature methods. PCR was carried out in a total volume of 100 μL containing 200 ng of genomic DNA, 80 pmol of each primer, 100 μmol/L of each deoxyribonucleoside triphosphate, 1.5 μmol/L of magnesium chloride, 10 μL of 10X PCR buffer and 1.0 U of Taq DNA polymerase. The amplification conditions were 95 °C for 5 min, followed by 30 cycles of 94 °C for 30 s, 55 °C for 45 s, 72 °C for 1 min, with a final extension at 72 °C for 10 min in a thermal cycler.

Statistical analysis

Data were shown as mean and range.
The resected polyps varied in size among the PJS patients, and histopathologically, no malignant components were found within these resected polyps.

**STK11 gene mutation**

All 3 cases in Family I exhibited the +658C>T nonsense mutation in exon 5 (Figure 4), which resulted in the production of a truncated protein (Q220X). In Family II, Case 4 had -252C>A and -193C>A in the promoter region, while no germline mutations were noted for Case 5. In Family III, Case 6 was found to have the +1062C>G (F342L) mutation in exon 8.

**DISCUSSION**

Mutations in the STK11 gene on chromosome 19p13.3 have been identified as the cause of PJS. STK11 is a highly conserved gene that extends over 23 kb and consists of nine exons, and one non-coding exon, coding for a 433-amino acid coding sequence and one non-coding exon. STK11 protein is primarily composed of three major domains, including an N-terminal non-catalytic domain, a catalytic kinase domain and a C-terminal regulatory domain. Although the exact function of STK11 as of yet remains unclear, prior studies have demonstrated that a mutation in the STK11 gene can lead to a loss of kinase activity. This loss of activity is most likely responsible for the development of the PJS phenotype. Codons 50-337 are responsible for encoding the catalytic kinase domain. It has been proposed that the STK11 gene may act as a tumor suppressor gene and thus, could be involved in early development of the pathogenesis in which hamartomas are converted into adenocarcinoma.
polyps that were seen in Case 6. Amos may explain the relatively indolent phenotypes, including domain, it might not affect the STK11 functions. This involved in the codons that encode the catalytic kinase amino acid substitution. Since this mutation was not Case 6 is a missense mutation that results in the F342L study.

Potential genotype-phenotype correlations in the current series of PJS patients, it was not possible to assess the potential genotype-phenotype correlations in the current study. Nevertheless, we could not detect any mutations in these subjects. While the absence of STK11 mutations does occasionally occur in some PJS patients, the reason for this remains unclear at the present time. STK11/LKB1 gene mutation is found in approximately 30%-70% of sporadic cases of PJS and 70% of affected individuals with a family history of the condition[1]. Recent studies have attempted to use the multiplex ligation dependent probe amplification analysis to screen for gene and exon scale mutations in a set of PJS cases in which the STK11 mutations could not be detected. These studies showed that the detection rates of STK11 mutations in PJS patients tended to be higher, with rates reaching nearly 80%-94%[10-12]. It is likely that with continued improvements in genetic testing that mutation detection rates will improve further, making genetic heterogeneity even less likely. The lack of identification of a STK11 gene mutation also suggests genetic mosaicism or additional PJS loci[1,3,30].

Figure 4  Serine/threonine kinase 11 germline mutation of +658C>T in exon5 that was identified in all the 3 Peutz-Jeghers syndrome patients in FamilyⅠ. PJS is associated with an increased risk of gastrointestinal and nongastrointestinal malignancies[2,3,28,36]. The most common sites for malignancy include colorectal, breast, stomach, small bowel, and pancreas. Since gastrointestinal hamartomatous polyps are benign, they were not initially thought to represent a premalignant condition[11,12]. However, several studies have shown that the distribution of the gastrointestinal cancers in PJS patients is similar to that of the hamartomatous polyps, in addition to clearly documenting that carcinoma arises in hamartoma[28,36]. As a result, surveillance GI endoscopy is now recommended for detection of cancer[28]. Moreover, the ability to be able to predict the histologic grade and invasion depth of gastrointestinal neoplastic lesions is of clinical importance. The NBI magnification classification scheme that was proposed by Kanao et al[17] has proven to be useful for both predicting the histology and for selecting optimal therapeutic strategies. In Kanao’s study, they examined the sensitivity and specificity of the various lesions for diagnosing carcinomas. Their results showed that the sensitivities and specificities of the type A lesions for hyperplastic polyps were 100% and 98.9%, while the type B lesions for tubular adenoma were 85.5% and 71.0%, respectively. The sensitivities and specificities of the type C1 lesions for diagnosis of tubular adenoma or mucosal/minimally invasive colorectal cancer diagnosis were 80.0% and 89.4%, while for the type C3 lesions for the diagnosis of carcinoma with massive submucosal invasion, they were 63.8% and 100%, respectively. Based on these findings, endoscopic resection should be select-
ed when type B and C1 lesions are present, while surgical resection should be selected for type C3 lesions. In the current study, we diagnosed the gastric polyps observed in our patients according to the NBI-based classification.

As seen in Table 2, all of these polyps were classified as type A in each of the cases and thus, they did not require further treatment. This suggests all of these polyps were of a hyperplastic (hamartomatous) histology type. On the other hand, the colorectal polyps were classified as B type polyps, and since they were larger than 5 mm in size, they were endoscopically resected. Regardless of the treatment, there were no complications noted in our series.

Small-bowel polyps are the most significant clinical feature of PJS. These hamartomas can lead to complications such as bowel obstruction and severe GI bleeding, which necessitates multiple emergency laparotomies and bowel resections. In the current study, 5 out of 6 cases had one or more laparotomies due to intussusception or other significant symptoms. Therefore, when small-bowel polyps were more than 10 mm in size in PJS patients, we performed endoscopic resection using DBE.

In the current study, a total of 79 small-bowel polyps were safely resected without serious complications in any of the patients. However, in another study that examined a larger number of PJS cases, the total complication rate after therapeutic DBE was performed was relatively higher, with 6.8% of the patients exhibiting complications. When taken together with the findings for our small case series, these results justify performing a future prospective multicenter study that is specifically designed to examine PJS patient treatment protocols.

We report two novel mutations of STK11 that are associated with PJS. Endoscopic management of GI polyps in PJS patients using DBE or colonoscopy appears to be both safe and effective, and may help to prevent emergency laparotomies and reduce the cancer risk. Additionally, NBI magnification endoscopic observation provides helpful information that can be used to select optimal therapeutic strategies for GI tumors in PJS.

COMMENTS

Background

Peutz-Jeghers syndrome (PJS) is an autosomal-dominant hereditary condition characterized by gastrointestinal (GI) hamartomatous polyps and mucocutaneous pigmentation. Mutations in the serine/threonine kinase 11 (STK11) gene play a causal role in PJS. Endoscopic polypectomy of GI polyps may help to prevent emergency laparotomies and reduce PJS-related cancer risk.

Research frontiers

PJS occurrence is primarily associated with germline mutations in the STK11/LKB1 gene, which are localized on the chromosomal segment 19p13.3. The gene spans 23 kb, and consists of nine coding exons and a final noncoding exon. The coded protein plays a role in cellular energy metabolism, cell polarization, p53-dependent apoptosis, and Wnt signal transduction. The germline mutation detection rates in PJS patients vary among reports, but recent studies which have searched for germline mutations using state-of-art techniques demonstrate between 80% and 94%. Most mutations are single base substitutions/insertions or small deletions that result in an abnormal truncated protein.

Innovations and breakthroughs

Although the exact function of STK11 as yet remains unclear, prior studies have demonstrated that a mutation in the STK11 gene can lead to a loss of kinase activity. This loss of activity is most likely responsible for the development of the PJS phenotype. Codons 50-337 are responsible for encoding the catalytic kinase domain. In the study, the authors identified STK11 mutations in two families. These mutations have never been reported in any database or in any previously published articles, which indicates that they are novel mutations. In particular, the <656C>T nonsense mutation that was found in exon 5 results in a truncated protein that may be non-functional due to a loss of the kinase activity. The +1062C>G (F342L) mutation seen in exon 5 is a missense mutation that results in the F342L amino acid substitution. Since this mutation was not involved in the codons that encode the catalytic kinase domain, it might not affect the STK11 functions, suggesting that individuals with these missense mutations have a later onset of symptoms.

Applications

It has been proposed that the STK11 gene may act as a tumor suppressor gene and thus, could be involved in early development of the pathogenesis in which hamartomas are converted into adenocarcinoma. It is useful in clinical management of PJS and to predict its clinical course to assess this gene mutations.

Terminology

The STK11 gene is located on chromosome 19p13.3 and the mutations in STK11 gene have been identified as the cause of PJS. STK11 is a highly conserved gene that extends over 23 kb and consists of nine exons, and one non-coding exon. STK11 protein is primarily composed of three major domains, including an N-terminal non-catalytic domain, a catalytic kinase domain and a C-terminal regulatory domain. PJS is a rare autosomal-dominant hereditary condition with incomplete penetrance that is characterized by hamartomatous polyps of the gastrointestinal tract and pigmented lesions of the buccal mucosa, perioral region and other sites. Variable penetrance and clinical heterogeneity make it difficult to determine the exact frequency of PJS. Most PJS patients develop significant hamartomatous polyps of the small bowel, with these polyps commonly arising in the stomach and colorectum.

Peer review

This is a good study in which authors explore mutations in STK11 gene in PJS with GI hamartomatous polyps. The results are interesting and suggest that endoscopic polypectomy of GI polyps in PJS patients appears to be useful to prevent emergency laparotomies and reduce the cancer risk.

REFERENCES

1. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4: 408-415 [PMID: 16616343 DOI: 10.1016/j.cgh.2005.11.005]
2. McGarrity TJ, Amos C. Peutz-Jeghers syndrome: clinicopathological and molecular alterations. Cell Mol Life Sci 2006; 63: 2135-2144 [PMID: 16952088 DOI: 10.1007/s00018-006-6080-0]
3. Beggs AD, Latchford AR, Vasey HF, Moslen G, Alonso A, Aretz S, Bartonario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hes EF, Järvinen H, Hyer W, Ponz de Leon M, Ridanpää M, Sampson JR, Stormorken A, Tejpar S, Temprano T, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105: 1258-164; author reply 1265 [PMID: 20051941 DOI: 10.1038/ajg.2009.725]
4. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105: 1258-164; author reply 1265 [PMID: 20051941 DOI: 10.1038/ajg.2009.725]
5. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine/threonine kinase. Nat Genet 1998; 18: 38-43 [PMID: 9425897 DOI: 10.1038/ng_0198-38]
6. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Höglund P, Järvinen H, Kristo P, Pinto K, Rickert M, Salovaara R, Toros T, Bodmer W, Olschwang S, Olsen AS, Stratton MR
de la Chapelle A, Aaltonen LA. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187 [PMID: 9428765 DOI: 10.1038/34432]

Boudeau J, Sapkota G, Alessi DR, LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003; 536: 119-165 [PMID: 12829253 DOI: 10.1016/S0014-5793(03)00642-2]

Baas AF, Kuipers J, van der Wel NN, Battle E, Koerten HK, Peters PJ, Clevers HC. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116: 457-466 [PMID: 15016379 DOI: 10.1016/S0092-8674(04)00114-X]

Martin SG, St Johnston D. A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature 2003; 421: 379-384 [PMID: 12540903 DOI: 10.1038/nature01296]

Aretz S, Stienen D, Uhlhaas S, Loff S, Bass W, Pagenstecher C, McLeod DR, Graham GE, Mangold E, Santer R, Propping P, Friedl W. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005; 26: 513-519 [PMID: 16287113 DOI: 10.1002/hum.20253]

Volikos E, Robinson J, Altmakuii K, Mecklin JP, Järvinen H, Westerman AM, de Rooij FW, Vogel T, Moeslein G, Lauonen V, Tomlinson IP, Silver AR, Aaltonen LA. LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 2006; 43: e18 [PMID: 16648371 DOI: 10.1136/jmg.2005.039875]

de Leng WW, Jansen M, Carvalho R, Polak M, Musler AR, Mlin AN, Keller J, Menko FH, Ito M, Ohashi S, Okamoto K, Fukuda E, Takeshima F, Hayashi Y, Yamamoto H, Hayashi T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu T, Ezoe Y, Hori K, Yukawa Y, Morita S, Muto M, Horimatsu
S, Schmiegel W. Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers. *Int J Colorectal Dis* 2010; 25: 97-107 [PMID: 19722776 DOI: 10.1007/s00384-009-0793-0]

36 **Hearle N**, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJ, de Rooij FW, Wilson JH, Hansmann A, Möslein G, Royer-Pokora B, Vogel T, Phillips RK, Spigelman AD, Houlston RS. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006; 12: 3209-3215 [PMID: 16707622 DOI: 10.1158/1078-0432.CCR-06-0083]

37 **Amos CI**, Keither-Cheteri MB, Sabripour M, Wei C, McGarritt TJ, Seldin MF, Nations L, Lynch PM, Fidler IH, Friedman E, Frazier ML. Genotype-phenotype correlations in Peutz-Jeghers syndrome. *J Med Genet* 2004; 41: 327-333 [PMID: 15121768 DOI: 10.1136/jmg.2003.010900]

38 **Buchet-Poyau K**, Mehenni H, Radhakrishna U, Antonarakis SE. Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. *Cytogenet Genome Res* 2002; 97: 171-178 [PMID: 12438709 DOI: 10.1159/000066620]

39 **Boardman LA**, Couch FJ, Burgart LJ, Schwartz D, Berry R, McDonnell SK, Schaid DJ, Hartmann LC, Schroeder J, Stratakis CA, Thibodeau SN. Genetic heterogeneity in Peutz-Jeghers syndrome. *Hum Mutat* 2000; 16: 23-30 [PMID: 10874301 DOI: 10.1002/1098-1004(200007)16: ]

40 **Perzin KH**, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature. *Cancer* 1982; 49: 971-983 [PMID: 7059931 DOI: 10.1002/1097-0142(19820301)49: ]

41 **Defago MR**, Higa AL, Campra JL, Paradelo M, Uehara A, Torres Mazzucchi MH, Videla R. Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. *Endoscopy* 1996; 28: 267 [PMID: 879752 DOI: 10.1055/s-2007-100447]